Evidence map›Paper›PMID 38163752›Full record

ArticleEmerging microbes & infections2024

Detection of anti-premembrane antibody as a specific marker of four flavivirus serocomplexes and its application to serosurveillance in endemic regions.

Guan-Hua Chen, Yu-Ching Dai, Szu-Chia Hsieh, Jih-Jin Tsai, Ava Kristy Sy, Mario Jiz, Celia Pedroso, Carlos Brites, Eduardo Martins Netto, Phyllis J Kanki and 5 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

Guan-Hua ChenDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Yu-Ching DaiDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Szu-Chia HsiehDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Jih-Jin TsaiTropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Ava Kristy SyNational Reference Laboratory for Dengue and Other Arbovirus, Virology Department, Research Institute for Tropical Medicine, Muntinlupa City, Philippines.
Mario JizImmunology Department, Research Institute for Tropical Medicine, Muntinlupa City, Philippines.
Celia PedrosoLAPI-Laboratório de Pesquisa em Infectologia-School of Medicine, Federal University of Bahia, Salvador, Brazil.
Carlos BritesLAPI-Laboratório de Pesquisa em Infectologia-School of Medicine, Federal University of Bahia, Salvador, Brazil.
Eduardo Martins NettoLAPI-Laboratório de Pesquisa em Infectologia-School of Medicine, Federal University of Bahia, Salvador, Brazil.
Phyllis J KankiDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Danielle R D SaundersDepartment of Biology, United States Air Force Academy, Colorado Springs, CO, USA.
Dana L VanlandinghamBiosecurity Research Institute and Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA.
Stephen HiggsBiosecurity Research Institute and Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA.
Yan-Jang S HuangBiosecurity Research Institute and Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA.
Wei-Kung WangDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.ORCID 0000-0002-6670-4663
University of Hawaiʻi at Mānoa · USKansas State University · USUniversidade Federal da Bahia · BRResearch Institute for Tropical Medicine · PHHarvard University · USKaohsiung Medical University · TWUnited States Air Force Academy · US

Funding

Sex-specific effects of obestity on Influenza A virus infection and immunityP20GM130448 · NIGMS · KANSAS STATE UNIVERSITY · PI WAITHAKA MWANGI · 2020 to 2026
$15.8M
Long-term safety and effectiveness of Dengvaxia in the PhilippinesR01AI186073 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI Wei-Kung Wang · 2024 to 2026
$1.5M
Multiplex Serodiagnostic Assays for Pathogenic Arboviruses in BrazilR01AI149502 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI WANG, WEI-KUNG · 2020 to 2023
$624k
NIAID NIH HHS R01 AI149502NIAID NIH HHS R01 AI186073NIGMS NIH HHS P20 GM130448
6 · The paper itself

Abstract

In the past few decades, several emerging/re-emerging mosquito-borne flaviviruses have resulted in disease outbreaks of public health concern in the tropics and subtropics. Due to cross-reactivities of antibodies recognizing the envelope protein of different flaviviruses, serosurveillance remains a challenge. Previously we reported that anti-premembrane (prM) antibody can discriminate between three flavivirus infections by Western blot analysis. In this study, we aimed to develop a serological assay that can discriminate infection or exposure with flaviviruses from four serocomplexes, including dengue (DENV), Zika (ZIKV), West Nile (WNV) and yellow fever (YFV) viruses, and explore its application for serosurveillance in flavivirus-endemic countries. We employed Western blot analysis including antigens of six flaviviruses (DENV1, 2 and 4, WNV, ZIKV and YFV) from four serocomplexes. We tested serum samples from YF-17D vaccinees, and from DENV, ZIKV and WNV panels that had been confirmed by RT-PCR or by neutralization assays. The overall sensitivity/specificity of anti-prM antibodies for DENV, ZIKV, WNV, and YFV infections/exposure were 91.7%/96.4%, 91.7%/99.2%, 88.9%/98.3%, and 91.3%/92.5%, respectively. When testing 48 samples from Brazil, we identified multiple flavivirus infections/exposure including DENV and ZIKV, DENV and YFV, and DENV, ZIKV and YFV. When testing 50 samples from the Philippines, we detected DENV, ZIKV, and DENV and ZIKV infections with a ZIKV seroprevalence rate of 10%, which was consistent with reports of low-level circulation of ZIKV in Asia. Together, these findings suggest that anti-prM antibody is a flavivirus serocomplex-specific marker and can be employed to delineate four flavivirus infections/exposure in regions where multiple flaviviruses co-circulate.

Indexed as

DengueDengue VirusFlavivirusFlavivirus InfectionsZika VirusZika Virus InfectionAnimalsAntibodies, ViralCross ReactionsSeroepidemiologic StudiesYellow fever virusAntibodies, Viralantibodyflaviviruspremembrane proteinserosurveillanceYellow fever virus

Identifiers

PMID38163752
PMCPMC10810658
OpenAlexW4390488605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.